

February 6, 2016

**BSE Limited**  
Corporate Service Department  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P.J. Tower  
Dalal Street, Fort  
Mumbai - 400 001

**The National Stock Exchange of India Ltd.**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
Mumbai – 400 051

Dear Sirs,

We enclose a copy of the Press Release being issued today.

This is for your kind information and records.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

  
Rajiv Shah  
Company Secretary



Encl: as above



**Ministry of Commerce (MOFCOM) China has reduced the Anti-Dumping Duty on Pyridine from Jubilant to 17.6%**

***Noida (UP), India, Saturday, February 6, 2016***

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, announced today that MOFCOM has reduced Anti-Dumping Duty on its Pyridine to 17.6% from existing 24.6% based on the review petition filed by the company.

The Company will continue to evaluate the market conditions and get the benefit of reduced duty going forward.

**About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

**For more information please contact:**

***For Investors***

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

***For Media***

Sudhakar Safaya / Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1034 / 1067  
E-mail: [sudhakar\\_safaya@jubl.com](mailto:sudhakar_safaya@jubl.com)  
[neha\\_garg@jubl.com](mailto:neha_garg@jubl.com)

Kanika Mittal  
Perfect Relations  
Ph: +91 9899574833  
E-mail: [kmittal@perfectrelations.com](mailto:kmittal@perfectrelations.com)



*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*